Bard's bladder cancer test approved in Japan:
This article was originally published in Clinica
CR Bard's BTA urine test for recurrent bladder cancer has been approved by the Japanese Ministry of Health and Welfare. The test, which has been shown to be more sensitive than urine cytology, will be used to monitor bladder cancer patients. It is already cleared for sale in the US and Europe and will be launched in June. Medicon, a joint-venture company of Bard, will sell the test in Japan.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.